Jan. 9 at 12:31 PM
$CDXS One of Codexis "potential" siRNA clients, Corsera health raised an oversubscribed
$80 million Series A to advance its cardiovascular disease prediction-and-prevention strategy . the company has initiated dosing in a Phase 1 trial of COR-1004, a subcutaneously administered siRNA targeting PCSK9. The study’s primary endpoint is safety and tolerability, with secondary measures including PCSK9 knockdown, LDL-C lowering, and pharmacokinetics. Corsera expects initial proof-of-concept data in 2026. Corsera said the Series A will also support development of COR-2003, an siRNA targeting angiotensinogen (AGT) to reduce blood pressure, with a Phase 1 trial anticipated to begin in mid-2026.
